Transgene Extends its myvac(R) Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
2026 Half-Year Results and Business Updatemyvac(R) — Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturingTG4050 — First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac(R) platform advancing in resected…